Servier has agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for up to $2.65 billion, including an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments. The deal centers on sevasemten, an investigational oral drug for Becker and Duchenne muscular dystrophies, which is in a pivotal cohort for BMD and a phase 2 trial for DMD. The acquisition is expected to close in the third quarter of 2026, after regulatory clearance and customary conditions. Servier says adding this neuromuscular program will strengthen its neurology and rare disease pipeline, while Edgewise will refocus entirely on its cardiovascular portfolio, including the heart‑muscle drug EDG‑7500.
Sources:
Ferrari's New EV Supercar Luce Fails To Impress Retail Traders
Edgewise拟向Servier出售肌营养不良业务，交易总额达26.5亿美元
Acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business
Servier completes the acquisition of Day One Biopharmaceuticals
Edgewise va céder son activité dédiée à la dystrophie musculaire à ...
Servier inks $2.6B buyout of Edgewise's muscular ...
Servier buys into muscular dystrophy with potentially $2.7B ...
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
Servier to Acquire Edgewise Muscular Dystrophy Business ...
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy ...
Edgewise Therapeutics to sell sevasemten for up to $2.65B
Servier to Acquire Edgewise Therapeutics' Muscular ...
Servier to buy Edgewise Therapeutics' muscular dystrophy drug